Evidence map›Paper›PMID 37246411›Full record

SynthesisHand (New York, N.Y.)2024

Surgical Management of Dupuytren Disease: A Systematic Review and Network Meta-analyses.

Silas Nann, Joshua Kovoor, James Fowler, James Kieu, Aashray Gupta, Joseph Hewitt, Christopher Ovenden, Suzanne Edwards, Stephen Bacchi, Jonathan Henry W Jacobsen and 2 more

Open access · hybridAbstract readSystematic ReviewNetwork Meta-Analysis
In one paragraph

Synthesis in Hand (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Trends in Treatment and Reimbursement of Dupuytren Disease.Journal of hand surgery global online · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Silas NannThe University of Adelaide, SA, Australia.ORCID 0000-0001-5264-1115
Joshua KovoorThe University of Adelaide, SA, Australia.
James FowlerThe Queen Elizabeth Hospital, Adelaide, SA, Australia.
James KieuRoyal Adelaide Hospital, SA, Australia.
Aashray GuptaThe University of Adelaide, SA, Australia.
Joseph HewittThe University of Adelaide, SA, Australia.
Christopher OvendenThe University of Adelaide, SA, Australia.
Suzanne EdwardsThe Queen Elizabeth Hospital, Adelaide, SA, Australia.
Stephen BacchiThe University of Adelaide, SA, Australia.
Jonathan Henry W JacobsenRoyal Australasian College of Surgeons, Adelaide, SA, Australia.
Richard HarriesThe Queen Elizabeth Hospital, Adelaide, SA, Australia.
Guy MaddernThe University of Adelaide, SA, Australia.
Queen Elizabeth Hospital · AURoyal Adelaide Hospital · AURoyal Australasian College of Surgeons · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDupuytren disease is a common fibroproliferative disease that affects the palmar fascia of the hands. Currently, there is limited consensus regarding the optimal therapy for this condition, with treatment decisions based largely on surgeon preference. Therefore, the aim of this study was to determine which treatments are the most effective for Dupuytren disease.

methodA systematic review and network meta-analyses were conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Medline, EMBASE, and Web of Science were searched for randomized trials comparing treatments for Dupuytren disease in adults. Eligible treatments included open limited fasciectomy, collagenase injection, and percutaneous needle fasciotomy. Study selection, data extraction, and quality appraisal were performed in duplicate. The methodological quality was evaluated with the Cochrane risk-of-bias critical appraisal tool.

resultsEleven randomized clinical trials were included in this study. At short-term (1-12 weeks) and long-term (2-5 years) time points, fasciectomy improved contracture release more than collagenase and needle fasciotomy as inferred by a lower total passive extension deficit. However, there was no difference between the groups regarding the best possible outcome at any time point. Fasciectomy was also superior in terms of recurrence and patient satisfaction compared with collagenase and needle fasciotomy, but only at later time points. There was no difference in skin damage-related and nerve damage-related complications following fasciectomy compared with other modalities. Risk of bias was generally moderate.

conclusionsFasciectomy provides superior long-term advantages in terms of patient outcomes when compared with collagenase and needle fasciotomy. Larger trials with better blinding of outcome assessors are needed in the future.

Indexed as

Dupuytren ContractureFasciotomyCollagenasesHumansRandomized Controlled Trials as TopicCollagenasescollagenase clostridium histolyticum injectionDupuytren diseasenetwork meta-analysisopen limited fasciectomypercutaneous needle fasciotomysystematic review

Identifiers

PMID37246411
PMCPMC11536719
OpenAlexW4378640089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.